U

Universitatsmedizin Mannheim | II.Medizinischen Klinik

Research site

(Unclaimed)

Location

Theodor-Kutzer-Ufer 1-3, Mannheim, Baden-Württemberg, Germany

Site insights

Top conditions

Top treatments

Valganciclovir

TAK-018

Vedolizumab

BMS-986165

Nanatinostat

Parent organization

This site is a part of Universitatsmedizin Mannheim

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 8 total trials

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone...

Active, not recruiting

Hepatocellular Carcinoma

Liver Cancer

Biological: Nivolumab

Other: Placebo

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammator...

Enrolling

Dermatomyositis

Myositis

Biological: EFG PH20 SC

Other: PBO

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphom...

Enrolling

EBV Associated Lymphoma

EBV Related Non-Hodgkin's Lymphoma

Drug: Nanatinostat in combination with valganciclovir